Dr. Baughman is Professor of Medicine at the University of Cincinnati. After completing undergraduate training at Yale University, he received his medical degree from Case Western Reserve School of Medicine. He joined the Internal Medicine staff at the University of Cincinnati after completing both an Internal Medicine residency and fellowship training in pulmonary diseases at the University of Cincinnati. His major research interests include: the treatment of sarcoidosis and bronchoalveolar lavage. Along with his long time collaborator Dr. Elyse Lower, he has developed several novel treatments for sarcoidosis, including methotrexate, thalidomide, leflunomide, and infliximab. Current studies include treatments for sarcoidosis associated fatigue and pulmonary hypertension due to sarcoidosis. He is on the editorial board of multiple subspecialty journals, and his publications include over 300 original papers mostly regarding various aspects of sarcoidosis and over 70 review articles and/or book chapters. He has edited several books on sarcoidosis and other interstitial lung diseases. He is on the editorial board of several journals, including American Journal of Respiratory and Critical Care Medicine and Chest. In addition, Dr. Baughman is the recent editor of books on sarcoidosis, interstitial lung disease, and ventilator associated pneumonia. He has been an active member of World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) since its inception and is President Emeritus. Daniel Culver is the Director of the Interstitial Lung Disease Program at Cleveland Clinic. He has directed the Sarcoidosis Centre of Excellence at Cleveland Clinic since 2005, and holds full staff appointments in the Department of Pulmonary Medicine and the Department of Pathobiology. He is the Chair of the Scientific Advisory Committee of the Foundation for Sarcoidosis Research, and a member of the Executive Committee for the Americas Association of Sarcoidosis and Other Granulomatous Disorders. He is the Chief Research Officer for the Respiratory Institute at Cleveland Clinic. He is a past recipient of the Bruce Hubbard Stewart Award and the HCOM Medal of Merit. He is a member of the ATS, ACCP, WASOG, and AASOG. His main interests include sarcoidosis, idiopathic pulmonary fibrosis, other granulomatous diseases, pulmonary alveolar proteinosis, and other interstitial lung diseases; he has written extensively on sarcoidosis and is an associate editor for Chest. He is President Elect of WASOG. David Birnie, MD, is staff cardiac electrophysiologist and Deputy Division Head of Cardiology at the University of Ottawa Heart Institute. He is also Director, Clinical Research, Division of Cardiology at the University of Ottawa Heart Institute and Associate Professor in the Division of Cardiology, Department of Medicine, at the University of Ottawa. Dr. Birnie leads the Ottawa region strategic research Innovation Cluster on Atrial Fibrillation. Dr. Birnie is a founding and current member of the Canadian Heart Rhythm Society Research Committee. He is chair of the first international guidelines for the diagnosis and management of cardiac sarcoidosis. He currently sits on both Canadian Institutes of Health Research (CIHR) and Heart and Stroke Foundation peer review panels. To date, he has been involved in over 385 peer-reviewed presentations, publications, and book chapters. In 2014, Dr. Birnie was awarded the University of Ottawa Heart Institute’s Clinical Science Investigator of the Year award. Dr. Birnie has been an invited speaker at major international conferences including the American Heart Association, Heart Rhythm Society and the Canadian Cardiovascular Society meeting. He has managed to combine work with his major hobby, serving as cardiologist for the Medical Advisory Committee of the Canadian Soccer Association.